Tung Michael Stephen 4

What Happened
Michael Tung, EVP & CFO of vTv Therapeutics (VTVT), was granted a derivative award on Feb 17, 2026 for 44,969 shares at an indicated price of $36.92 per share, a total value of approximately $1,660,255. The filing classifies this as a grant/award (derivative), i.e., an equity-based compensation award rather than an open-market purchase.

Key Details

• Transaction date: 2026-02-17; Form 4 filed 2026-02-18 (timely filing).
• Award: 44,969 derivative shares; price shown $36.92 per share; total indicated value ~$1,660,255.
• Shares owned after transaction: not specified in the reported filing.
• Footnote: options vest 25% on the first anniversary of the grant date and in equal quarterly installments thereafter.
• Transaction code: A (award/acquisition); derivative award (likely option-based per footnote).

Context
This was a compensatory equity award tied to Tung’s role, with a multi-period vesting schedule — meaning the recipient cannot realize much value immediately. Such grants are common for executive compensation and do not, by themselves, indicate a buy or sell decision by the insider.